Loading…
Employees: 5,019
Size Lumexa Imaging (LMRI) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.29B, the 2089th largest of 3,117 United States companies the cockpit tracks. Shares closed at $13.43 on 6 Nov 2026.
Performance Over six months the shares gained 28.9%, against +20.6% for the median peer and -1.1% for the United States market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 7.8% over the last twelve months (peer median +7.4%); the operating margin is 2.6% (peer median 6.2%).
Valuation It trades at 18.6× forward earnings against a peer median of 30.4× (6th cheapest of 16).
Capital Return on invested capital runs 6.5 points below its cost of capital (7.9% WACC).
Short interest Short interest is 2.0% of the free float (15 Oct 2026).
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | n/a | $1.02B | $949M | $936M |
| Revenue growth | — | +8% | +1% | — |
| Gross profit | n/a | $117M | $54.1M | $42.3M |
| EBITDA | n/a | $82.6M | $40.9M | $59.2M |
| Net income | n/a | -$47.1M | -$94.1M | -$122M |
| Free cash flow | n/a | -$6.40M | $13.0M | $13.5M |
| Capital expenditure | n/a | $23.5M | $27.8M | $24.0M |
| Total debt | $975M | $963M | $1.31B | $1.30B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LMRI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +30.0% | +4.8% | 2nd highest of 21 |
| 6-month return | +28.9% | +20.6% | 8th highest of 21 |
| Distance from 52-week high | -30.9% | -16.0% | 3rd lowest of 21 |
| Revenue growth (TTM) | +7.8% | +7.4% | 11th highest of 21 |
| Operating margin | 2.6% | 6.2% | 7th lowest of 21 |
| Forward P/E | 18.6× | 30.4× | 6th cheapest of 16 |
| ROIC minus cost of capital | -6.5 pp | -3.1 pp | 6th lowest of 20 |
| EV / EBITDA | 26.6× | 11.6× | 5th most expensive of 17 |
| Net debt / EBITDA | 11.0× | 1.3× | 2nd most indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lumexa Imaging LMRI | United States | $1.29B | +29% | +8% | 3% | 18.6× | n/a | n/a |
| OPKO Health OPK | United States | $1.29B | +52% | -11% | -29% | n/a | n/a | n/a |
| Diagnostyka DIA.WA | Poland | $1.29B | -5% | +19% | 15% | 18.4× | 6.9% | +18.9% |
| Pennant PNTG | United States | $1.27B | +1% | +38% | 6% | 24.0× | 21.1% | +19.4% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +12% | +20% | 18% | 45.6× | 32.4% | +10.5% |
| Nutex Health NUTX | United States | $1.24B | +32% | +7% | 43% | 7.2× | -19.5% | +253.5% |
| H.U.Group 4544.T | Japan | $1.35B | +24% | +1% | 2% | 41.0× | 10.1% | +2.1% |
| GoodRx GDRX | United States | $1.20B | +20% | -2% | 12% | 10.4× | 6.8% | +7.7% |
| Clariane CLARI.PA | France | $1.40B | -20% | +1% | 6% | 8.6× | 6.7% | +6.5% |
| Novogene 688315.SS | China | $1.16B | +31% | +6% | 7% | 35.7× | 17.1% | +8.2% |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 30.4× | 19.9% | +13.0% |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | n/a | n/a | n/a |
| Regis Healthcare REG.AX | Australia | $1.05B | -17% | +17% | 4% | 25.1× | 14.6% | +14.4% |
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | n/a | -5.2% | +18.3% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 64.3× | 39.3% | +16.7% |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 15.8× | 1.7% | +7.7% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 40.1× | 15.0% | -5.1% |
| AdaptHealth AHCO | United States | $1.00B | +8% | -3% | 3% | n/a | 16.3% | +25.2% |
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | n/a | n/a | n/a |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 103.7× | 56.0% | +8.9% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 89.1× | 41.9% | +26.9% |